InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
InMed Pharmaceuticals (NASDAQ: INM) has published a peer-reviewed study in Biofactors demonstrating cannabinol's (CBN) anti-inflammatory effects and its potential for treating skin diseases. The research, conducted with Dr. Mauro Maccarrone, shows that CBN prevents keratinocyte inflammation through various mechanisms, including TRPV1 receptor activation and modulation of endocannabinoid system elements. The study revealed CBN's ability to reduce pro-inflammatory cytokines while increasing anti-inflammatory ones, supporting its therapeutic potential for conditions like psoriasis, atopic dermatitis, and pruritus.
InMed Pharmaceuticals (NASDAQ: INM) ha pubblicato uno studio sottoposto a revisione paritaria su Biofactors che dimostra gli effetti anti-infiammatori del cannabinolo (CBN) e il suo potenziale per trattare malattie della pelle. La ricerca, condotta con il Dr. Mauro Maccarrone, evidenzia che il CBN previene l'infiammazione dei cheratinociti attraverso vari meccanismi, inclusa l'attivazione del recettore TRPV1 e la modulazione degli elementi del sistema endocannabinoide. Lo studio ha rivelato la capacità del CBN di ridurre le citochine pro-infiammatorie aumentando quelle anti-infiammatorie, supportando il suo potenziale terapeutico per condizioni come psoriasi, dermatite atopica e prurito.
InMed Pharmaceuticals (NASDAQ: INM) ha publicado un estudio revisado por pares en Biofactors que demuestra los efectos antiinflamatorios del cannabinol (CBN) y su potencial para tratar enfermedades de la piel. La investigación, realizada con el Dr. Mauro Maccarrone, muestra que el CBN previene la inflamación de los queratinocitos a través de varios mecanismos, incluida la activación del receptor TRPV1 y la modulación de los elementos del sistema endocannabinoide. El estudio reveló la capacidad del CBN para reducir las citoquinas pro-inflamatorias mientras aumenta las antiinflamatorias, apoyando su potencial terapéutico para condiciones como la psoriasis, la dermatitis atópica y el prurito.
인메드 제약(InMed Pharmaceuticals, NASDAQ: INM)은 Biofactors에 칸나비놀(CBN)의 항염증 효과와 피부 질환 치료 가능성을 보여주는 동료 평가 연구를 발표했습니다. 마우로 마카로네 박사와 함께 진행된 연구는 CBN이 각질세포의 염증을 예방한다는 것을 여러 가지 메커니즘, 즉 TRPV1 수용체의 활성화와 엔도칸나비노이드 시스템 요소의 조절을 통해 보여줍니다. 이 연구는 CBN이 프로염증성 사이토카인을 감소시키는 능력과 함께 항염증성 사이토카인을 증가시키는 능력을 밝혀내어, 건선, 아토피성 피부염 및 가려움증과 같은 질환에 대한 치료 잠재력을 지지합니다.
InMed Pharmaceuticals (NASDAQ: INM) a publié une étude évaluée par des pairs dans Biofactors, démontrant les effets anti-inflammatoires du cannabinol (CBN) et son potentiel pour traiter les maladies de la peau. La recherche, menée avec le Dr Mauro Maccarrone, montre que le CBN empêche l'inflammation des kératinocytes par divers mécanismes, y compris l'activation du récepteur TRPV1 et la modulation des éléments du système endocannabinoïde. L'étude a révélé la capacité du CBN à réduire les cytokines pro-inflammatoires tout en augmentant celles anti-inflammatoires, soutenant ainsi son potentiel thérapeutique pour des conditions telles que le psoriasis, la dermatite atopique et le prurit.
InMed Pharmaceuticals (NASDAQ: INM) hat eine von Experten begutachtete Studie in Biofactors veröffentlicht, die die entzündungshemmenden Effekte von Cannabinol (CBN) und sein Potenzial zur Behandlung von Hautkrankheiten zeigt. Die Forschung, die in Zusammenarbeit mit Dr. Mauro Maccarrone durchgeführt wurde, zeigt, dass CBN die Entzündung von Keratinozyten verhindert, und zwar durch verschiedene Mechanismen, einschließlich der Aktivierung des TRPV1-Rezeptors und der Modulation von Elementen des Endocannabinoid-Systems. Die Studie offenbarte die Fähigkeit von CBN, pro-inflammatorische Zytokine zu reduzieren und gleichzeitig entzündungshemmende Zytokine zu erhöhen, was sein therapeutisches Potenzial für Erkrankungen wie Psoriasis, atopische Dermatitis und Juckreiz unterstützt.
- Scientific validation of CBN's anti-inflammatory properties through peer-reviewed publication
- Demonstrated multiple mechanisms of action for inflammatory skin disease treatment
- Potential therapeutic applications in multiple skin conditions
- None.
Insights
This study reveals significant scientific findings about cannabinol's (CBN) anti-inflammatory properties, but has immediate market impact. The research demonstrates CBN's ability to modulate the endocannabinoid system and reduce inflammation in skin cells, supporting its potential use in treating conditions like psoriasis and dermatitis.
The molecular mechanisms identified - including TRPV1 activation and cytokine modulation - provide valuable scientific validation for InMed's drug development approach. However, this is early-stage research that requires substantial additional development before commercialization. While scientifically meaningful, the study represents a preliminary step in the drug development pipeline rather than a near-term revenue catalyst.
- Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects
- Supports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritus
- Anti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that a peer-reviewed scientific study entitled "Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes" has been published in the international journal Biofactors. This Company-sponsored study demonstrates the biological activity of cannabinol ("CBN") and its potential anti-inflammatory effects in skin diseases.
The study, conducted in collaboration with Dr. Mauro Maccarrone at Università degli Studi dell'Aquila, investigated how CBN modulates the major elements of the endocannabinoid system ("ECS") and activated receptors known to be involved in the inflammatory pathways of the skin. CBN was found to:
- prevent keratinocyte inflammation via vanilloid receptor 1 ("TRPV1");
- express mitogen-activated protein kinases in inflamed keratinocytes;
- modulate the enzymes that regulate both AEA and 2-AG (endocannabinoids);
- increase expression of cannabinoid receptor 1 ("CB1") at the gene level; and
- reduce the release of the pro-inflammatory cytokines: interleukin (IL)-8, IL-12, IL-31 while increasing the release of the anti-inflammatory cytokine, IL-10.
The anti-inflammatory activity demonstrated in this study suggests the potential of cannabinol to regulate epidermal functions and provide a protective role in the skin.
"This peer-reviewed study provides scientific evidence of the distinct anti-inflammatory biological activity of cannabinol," said Dr. Mauro Maccarrone, one of InMed's scientific advisors. "Results from this study further support cannabinol's therapeutic and cosmetic application in inflammatory skin conditions."
"Our drug development programs have been focused on the role of inflammation in various diseases, such as Alzheimer's disease, age-related macular degeneration and epidermolysis bullosa and how rare cannabinoids and their analogs may be able to modulate the inflammation process," commented InMed's Senior VP, Preclinical Research and Development, Dr. Eric Hsu. "This important research into endocannabinoid system modulation not only helps in the advancement and selection of InMed's potential drug candidates but also deepens our understanding of the ECS targets involved in specific disease areas. The endocannabinoid system is involved in almost every aspect of the body's functioning, holding significant potential for therapeutic intervention."
The journal article can be accessed here: https://iubmb.onlinelibrary.wiley.com/doi/10.1002/biof.2122.
Dr. Mauro Maccarrone is a leader in cannabinoid research and is the recipient of the 2025 Career Achievement Award by the International Cannabinoid Research Society and is a member of the Company's Scientific Advisory Board.
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: ir@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; the biological activity of CBN and its potential anti-inflammatory effects in skin diseases; cannabinol's therapeutic and cosmetic application in inflammatory skin conditions; the endocannabinoid system's involvement in almost every aspect of the body's functioning and holding significant potential for therapeutic intervention.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/230523
FAQ
What are the key findings of InMed's (INM) 2024 cannabinol study?
Which skin conditions could InMed's (INM) cannabinol potentially treat?
Where was InMed's (INM) 2024 cannabinol research published?
